Title Characterization of immunological responses in patients with severe fever with thrombocytopenia syndrome: A cohort study in China
Authors Lu, Qing-Bin
Cui, Ning
Hu, Jian-Gong
Chen, Wei-Wei
Xu, Wen
Li, Hao
Zhang, Xiao-Ai
Ly, Hinh
Liu, Wei
Cao, Wu-Chun
Affiliation Peking Univ, Sch Publ Hlth, Beijing 100191, Peoples R China.
Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing 100071, Peoples R China.
Peoples Liberat Army, Hosp 154, Xinyang 464000, Peoples R China.
Peoples Liberat Army, Hosp 302, Beijing 100039, Peoples R China.
Univ Minnesota, St Paul, MN 55108 USA.
Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, 20 Dong Da St, Beijing 100071, Peoples R China.
Keywords Severe fever with thrombocytopenia syndrome
Immunological response
Cohort study
Humoral immunity
HEMORRHAGIC-FEVER
SYNDROME VIRUS
EPIDEMIOLOGY
PATHOGENESIS
BUNYAVIRUS
PROGRESS
Issue Date 2015
Publisher vaccine
Citation VACCINE.2015,33,(10),1250-1255.
Abstract Background: The immunological responses of patients with severe fever with thrombocytopenia syndrome (SFTS) remain largely unknown. We aim to study the magnitude and sustainability of host immune responses and their correlation with clinical, virological and hematological parameters. Methods: A longitudinal cohort study was performed in a SETS reference hospital. The sequential immunological evaluation was determined for SFTSV infected patients, including anti-SFTSV IgM, IgG antibodies and the lymphocyte subsets. Results: Altogether 298 laboratory-confirmed SFTS cases were analyzed, from whom 55 patients were followed after convalescence. SFTSV specific IgM antibody could be detected at medium of 9 days, surged to peak levels by 4 weeks, and remained persistent until 6 months after disease onset. SFTSV specific IgG antibody could be detected at medium of 6 weeks; surged to peak levels by 6 months, and remained positive in most of the patients even at 3 years after infection. SFTS patients experienced obvious T cell, B cell and NK cells loss during the first week of infection, which was rapidly restored to normal levels. A significantly lower level of humoral immunity was identified concurrently from severe disease, especially in acute phase of the infection. These abnormalities can be used as a potential indicator in the prediction of an adverse clinical outcome. Conclusions: Information gained from this study have clinical significance in enhancing our understanding of SFTS immunological characteristics and the disease pathogenesis. (C) 2015 Elsevier Ltd. All rights reserved.
URI http://hdl.handle.net/20.500.11897/188346
ISSN 0264-410X
DOI 10.1016/j.vaccine.2015.01.051
Indexed SCI(E)
PubMed
Appears in Collections: 公共卫生学院

Web of Science®


24

Checked on Last Week

Scopus®



Checked on Current Time

百度学术™


0

Checked on Current Time

Google Scholar™





License: See PKU IR operational policies.